MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
common stock, net of...
$380,514K
Net cash provided by
financing activities
$389,875K
Net change in cash,
cash equivalents and...
$12,813K
Canceled cashflow
$377,062K
Proceeds from sales and
maturities of investment...
$302,889K
Stock-based compensation
$29,680K
Depreciation and
amortization
$1,160K
Noncash lease expense
$703K
Loss on disposal of
property and equipment
-$20K
Net cash used in
investing activities
-$252,359K
Net cash used in
operating activities
-$124,703K
Canceled cashflow
$302,889K
Canceled cashflow
$31,563K
Purchases of investment
securities
$554,428K
Net loss
-$127,845K
Purchases of property and
equipment
$820K
Accounts payable and
accrued expenses,...
-$12,064K
Prepaid expenses and
other assets
$7,024K
Trade accounts
receivable
$5,091K
Accretion of purchase
discounts and...
$2,220K
Inventory
$909K
Operating lease
liabilities
-$685K
Deferred revenue
-$428K
Back
Back
Cash Flow
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)
source: myfinsight.com